TD Cowen upgrades UnitedHealth, citing potential Optum Health recovery

On November 20, 2026, TD Cowen upgraded UnitedHealth from hold to buy and raised its price target from $402 to $455. The new target implied 38% upside from the stock’s November 19 close.

Analyst Ryan Langston said he saw a credible path to earnings-per-share growth in the mid-to-high teens through at least 2028, citing Medicare Advantage benefit design, a potential Optum Health recovery and improvement in UnitedHealth’s commercial and Medicare-Medicaid Dual Complete businesses. He expected Optum Health’s margins to expand again in 2027 and identified external growth at Optum Rx and commercialization of Optum Insight’s AI-first products as areas to watch.

UnitedHealth shares had fallen 14% over the preceding three months amid mounting policy headwinds. Earlier in November, the Centers for Medicare & Medicaid Services proposed an anti-fraud rule aimed at identifying and eliminating abuse and fraud in Medicare and Medicare Advantage. The proposal raised concerns that UnitedHealth’s Medicare Advantage business could face greater scrutiny; it was not an enacted rule. Langston said those uncertainties would not derail progress at Optum Health.

TD Cowen’s upgrade aligned with the prevailing analyst view: 25 of the 28 analysts covering UnitedHealth rated the stock buy or strong buy, according to LSEG data cited in the November 20 report.

Further reading